The therapeutic effect and real feedback of Avonib (Tosuvo) on leukemia patients

Ivosidenib is mainly used to treat patients with acute myeloid leukemia (AML) who carry IDH1 gene mutations. Clinical studies have shown that ivonib can effectively inhibit the activity of IDH1 mutant enzyme and reduce the level of carcinogenic metabolite 2-HG, thereby promoting the differentiation of leukemia cells and reducing abnormal proliferation. This mechanism is different from traditional chemotherapy, allowing some patients who are not suitable for intensive chemotherapy to receive treatment opportunities.

In terms of actual efficacy, multiple clinical trial data show that the overall response rate of ivonib monotherapy can reach about 30%, and some patients can achieve complete remission. Especially in elderly patients or patients with relapsed/refractory AML who have failed previous treatments, ivonib has shown good tolerability and controllable safety. Common side effects include fatigue, nausea, leukopenia, and arrhythmia, but most can be alleviated through dose adjustment or symptomatic treatment.

Real feedback from patients shows that after using ivonib, some patients' blood conditions gradually improved and their quality of life was relatively improved. Especially for elderly patients who cannot tolerate traditional chemotherapy, the convenience of oral medication and low side effects allow patients to receive treatment at home, reducing the frequency of hospitalization and psychological pressure. At the same time, some patients can significantly reduce the risk of infection and anemia symptoms after several months of treatment.

Although ivonib has shown a positive effect in the treatment ofAML, the efficacy varies due to individual differences, and individualized treatment plans still need to be developed based on genetic testing, disease assessment and combined treatment options. Patients should closely monitor blood and heart function during use, and follow doctor's instructions for regular review to ensure the best balance between efficacy and safety.

Keyword tags:

Avosidenib, IDH1 mutation, acute myeloid leukemia, AML, targeted therapy, efficacy feedback, complete remission, side effect management, elderly patients

Reference materials:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007650/